ArticleApplied health economics and health policy2022
Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.
Article in Applied health economics and health policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cost-effectiveness of dialectical behavioural therapy versus treatment as usual for autism with suicidal behaviours: single-blind randomised controlled trial.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Trial
- Cost-effectiveness of a real-time screening strategy for bacterial vaginosis using qPCR to prevent preterm birth: results from a randomized prospective multicenter study.Cost effectiveness and resource allocation : C/E · 2026Article
- Considering research waste in economic evaluations of low-dose computed tomography screening for lung cancer.International journal of technology assessment in health care · 2026Review
- Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States.Frontiers in public health · 2026Article
- Budget impact analysis of introducing digital breast tomosynthesis in breast cancer screening in Italy.La Radiologia medica · 2024Article
- Estimated US Pediatric Hospitalizations and School Absenteeism Associated With Accelerated COVID-19 Bivalent Booster Vaccination.JAMA network open · 2023Article
- Protocol for a multicenter study on effectiveness and economics of the Back At work After Surgery (BAAS): a clinical pathway for knee arthroplasty.BMC musculoskeletal disorders · 2023Article
- Transforming global approaches to chronic disease prevention and management across the lifespan: integrating genomics, behavior change, and digital health solutions.Frontiers in public health · 2023Review
- Return on Investment of the COVID-19 Vaccination Campaign in New York City.JAMA network open · 2022Article
Corrections and comments
- Erratum for
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.